Serono Genetics Institute S.a.

Genset S.a.

Severin Jobert

Jean-Baptiste Dumas Milne Edwards

Lydie Bougueleret

Jean-Yves Giordano

Bernard Bihain

Hiroaki Tanaka

Frances Yen-Potin

Stephane Bejanin

Blake Denison

Barbara A Chicca

John Chicca

The sequences of 5' ESTs and consensus contigated 5&#x2032;ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5&#x2032; ESTs and consensus contigated 5&#x2032;ESTs may be to obtain cDNAs and genomic DNAs corresponding to the 5&#x2032; ESTs and consensus contigated 5&#x2032;ESTs. The 5&#x2032; ESTs and consensus contigated 5&#x2032;ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5&#x2032; ESTs and consensus contigated 5&#x2032;ESTs. The 5&#x2032; ESTs and consensus contigated 5&#x2032;ESTs may also be used to design expression vectors and secretion vectors.

ESTs and encoded human proteins

The sequences of cDNAs encoding secreted proteins are disclosed. The cDNAs can be used to express secreted proteins or fragments thereof or to obtain antibodies capable of specifically binding to the secreted proteins. The cDNAs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. The cDNAs may also be used to design expression vectors and secretion vectors.

Complementary DNAs encoding proteins with signal peptides

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

Full-length human cDNAs encoding potentially secreted proteins

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.

GSSP4 polynucleotides and polypeptides and uses thereof

The sequences of 5&prime; ESTs and consensus contigated 5&prime; ESTs derived from mRNAs encoding secreted proteins are disclosed. The 5&prime; ESTs and consensus contigated 5&prime; ESTs may be used to obtain cDNAs and genomic DNAs corresponding to the 5&prime; ESTs and consensus contigated 5&prime; ESTs. The 5&prime; ESTs and consensus contigated 5&prime; ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5&prime; ESTs and consensus contigated ESTs. The 5&prime; ESTs and consensus contigated 5&prime; ESTs may also be used to design expression vectors and secretion vectors.

Growing community of inventors

Paris, France

Severin Jobert